Document Detail


Cost/Utility study of peritoneal dialysis and hemodialysis in Chile.
MedLine Citation:
PMID:  17468491     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In Chile the reimbursement/patient/year for chronic peritoneal dialysis (PD) is US$14,654 and for chronic hemodialysis (HD) US$10,909. However, no study comparing global (direct plus indirect) costs has been performed in our country. Our research objective was to compare global costs and quality of life between the two therapies. Patients (n = 159) from five selected dialysis units in Chile [57 patients on PD (50 on automated PD) and 102 on standard HD (3 x 4 hours weekly)] were retrospectively studied. No patient had previously received the alternate therapy. Items analyzed were quality of life, customer satisfaction, direct and indirect costs, annual global costs, and cost/utility index. Mean age on HD was 54.14 +/- 16.01 years and on PD 49.76 +/- 18.88 years (p > 0.05). No differences in the distribution of diabetic patients between the therapies were found. Hemodialysis and PD groups did not have differences in the quality of life index, although there was better customer satisfaction with PD than with HD. Direct and indirect costs were calculated. We found significant differences in favor of PD in erythropoietin consumption (2.24 +/- 1.57 vials/week on HD and 1.35 +/- 0.85 vials/week on PD, p < 0.05) and working time (31.0 +/- 13.3 hours/week on HD and 38.5 +/- 12.2 hours/week on PD, p < 0.05). The quality life index (Health-Related SF-36 Health Survey) was 65.75 on HD and 66.88 on PD. Annual global costs were US$20,803 for HD and US$20,742 for PD. The cost/utility index was 3.16 for HD and 3.10 for PD. Patients on PD have an advantage related to erythropoietin consumption and working capacity compared with HD patients. Addition of related indirect costs to reimbursements gives a more accurate insight into treatment costs. Considering all these parameters, we did not find significant differences between HD and PD in quality life index, cost/utility index, or annual global cost in this Chilean end-stage renal disease population.
Authors:
Alejandro Pacheco; Antonio Saffie; Rubén Torres; Cristian Tortella; Cristian Llanos; Daniel Vargas; Vito Sciaraffia
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis     Volume:  27     ISSN:  0896-8608     ISO Abbreviation:  Perit Dial Int     Publication Date:    2007 May-Jun
Date Detail:
Created Date:  2007-04-30     Completed Date:  2007-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8904033     Medline TA:  Perit Dial Int     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  359-63     Citation Subset:  IM    
Affiliation:
Nephrology Section, Department of Medicine, University of Chile Clinical Hospital, Santos Dumont 999, Independencia, Santiago 838-0456, Chile. apacheco@redclinicauchile.cl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Chile
Cost-Benefit Analysis*
Female
Humans
Male
Middle Aged
Patient Satisfaction
Peritoneal Dialysis / economics*,  utilization*
Quality of Life
Renal Dialysis / economics*,  utilization*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pregnancy in end-stage renal disease patients and treatment with peritoneal dialysis: report of two ...
Next Document:  Diastolic heart failure in anaesthesia and critical care.